FOXA1 expression and survival outcomes in triple-negative breast cancer: A retrospective cohort study

Triple-negative breast cancer (TNBC) remains the most aggressive breast cancer subtype, with the poorest prognosis among all forms of breast cancer. FOXA1 is a well-known pioneer factor in luminal breast cancer, however, despite its vital role in this tumor subtype, detailed information about FOXA1 expression and function in TNBC is notably lacking. This gap highlights the importance of exploring whether FOXA1 plays different roles across breast cancer subtypes. Accordingly, the present study aimed to assess the independent prognostic value of FOXA1 expression in a well-characterized cohort of 283 women with TNBC, evaluating its association with progression-free survival (PFS), overall survival (OS), and distant metastasis, and to determine whether this association is independent of the systemic treatment received. Initial analyses employed chi-square and t-tests to identify associations, followed by multivariate logistic and Cox regression models to determine independent predictors. Survival analyses were performed using Kaplan-Meier curves, with comparisons made using the log-rank test. The median age of patients was 69 years. FOXA1 positivity was significantly associated with grade II tumors (p < 0.001) and Ki-67 levels lower than 20% (p < 0.001). In multivariate analysis, FOXA1 was shown to be a poor prognostic factor for PFS (HRa = 1.68; 95% CI: 1.13-2.48; p = 0.009). Furthermore, in treatment-adjusted models, FOXA1 expression remained as an independent predictor of poor PFS (HRa = 1.96; 95% CI: 1.29-2.98; p = 0.001). These findings establish FOXA1 as an independent prognostic biomarker for disease progression in TNBC, with its adverse impact on PFS persisting regardless of the chemotherapeutic regimen administered.

Authors

Institutions

Publication Details

Journal
PLoS ONE
Published
2026-11-13
DOI
https://doi.org/10.1371/journal.pone.0362480
Primary Topic
Breast Cancer Treatment Studies
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

FOXA1 expression and survival outcomes in triple-negative breast cancer: A retrospective cohort study

Nelson Rangel, Angela V. Fonseca-Benítez, David Díaz‐Báez, Milena Rondón‐Lagos et al.
1 links
PLoS ONE
Breast Cancer Treatment Studies
article

FOXA1 expression and survival outcomes in triple-negative breast cancer: A retrospective cohort study

Nelson Rangel, Angela V. Fonseca-Benítez, David Díaz‐Báez, Milena Rondón‐Lagos, Giulia Cappella, Isabella Castellano
article en

Abstract

Triple-negative breast cancer (TNBC) remains the most aggressive breast cancer subtype, with the poorest prognosis among all forms of breast cancer. FOXA1 is a well-known pioneer factor in luminal breast cancer, however, despite its vital role in this tumor subtype, detailed information about FOXA1 expression and function in TNBC is notably lacking. This gap highlights the importance of exploring whether FOXA1 plays different roles across breast cancer subtypes. Accordingly, the present study aimed to assess the independent prognostic value of FOXA1 expression in a well-characterized cohort of 283 women with TNBC, evaluating its association with progression-free survival (PFS), overall survival (OS), and distant metastasis, and to determine whether this association is independent of the systemic treatment received. Initial analyses employed chi-square and t-tests to identify associations, followed by multivariate logistic and Cox regression models to determine independent predictors. Survival analyses were performed using Kaplan-Meier curves, with comparisons made using the log-rank test. The median age of patients was 69 years. FOXA1 positivity was significantly associated with grade II tumors (p < 0.001) and Ki-67 levels lower than 20% (p < 0.001). In multivariate analysis, FOXA1 was shown to be a poor prognostic factor for PFS (HRa = 1.68; 95% CI: 1.13-2.48; p = 0.009). Furthermore, in treatment-adjusted models, FOXA1 expression remained as an independent predictor of poor PFS (HRa = 1.96; 95% CI: 1.29-2.98; p = 0.001). These findings establish FOXA1 as an independent prognostic biomarker for disease progression in TNBC, with its adverse impact on PFS persisting regardless of the chemotherapeutic regimen administered.

PLoS ONEVol. 21(11)
Universidad El Bosque (CO), Pedagogical and Technological University of Colombia (CO), Pontificia Universidad Javeriana (CO), University of Turin (IT)
Ministerio de Ciencia, Tecnología e Innovación, Pontificia Universidad Javeriana
Good health and well-being
Breast Cancer Treatment Studies
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon